Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sichuan Clover Doses First Patient in China Trial of Novel Cancer Biologic

publication date: Sep 10, 2019

Sichuan Clover Biopharma has dosed the first patient in a China Phase I trial of its fully-human TRAIL-Trimer fusion protein in cancer patients with peritoneal carcinomatosis. Clover described PC as a loco-regional disease defined as tumor dissemination inside the peritoneal cavity that often stems from gastrointestinal tumors. SCB-313 is a novel fusion protein consisting of TRAIL (TNF-related apoptosis-inducing ligand) and Clover's Trimer-Tag©, which allows the molecule to be trimerized. Clover believes its trimerized fusion proteins will be effective against previously undruggable targets.. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China